Dr Marie-Paule Kieny is Director of Research at Inserm in Paris, in charge of the Priority Research Program on Antibiotic Resistance initiated by France in 2019 as part of the Investment Program for the Future (Programme d'Investissements d'Avenir). She also represents France on the Board of Directors of the Joint Programming Initiative on Antimicrobial Resistance, JPIAMR. Between March 24 and July 10, 2020, she was a member of the Research and Expertise Analysis Committee (CARE), set up by President Macron, which brough together 12 researchers and physicians to advise the government on treatments, vaccines and tests against COVID-19. Since June 2020, she chairs the French Scientific Committee on COVID-19 vaccine, which mandate is to: - Map candidate vaccines in clinical trials or likely to reach this stage in over the next 12 months; - Provide up-to-date scientific and technical advice on candidate vaccines that have reached the stage of clinical evaluation, to be retained within the framework of the French strategy; - Provide specific advice on the vaccine candidates to be given priority access to the platform national vaccine clinical trials; - Advise on documents provided by the government regarding the establishment of a French vaccination policy; - Exchange with similar committees of the European Commission, other Member States of the European Union or international. Besides her responsibilities in France, Marie-Paule Kieny is Chair of the Board of Directors of the Drugs for Neglected Diseases Initiative (DNDi, Geneva, Switzerland) and of the Medicines Patent Pool Foundation (MPPF, Geneva, Switzerland). She is also Vice-Chair of the Board of the Global Antibiotic Research and Development Partnership (GARDP, Geneva, Switzerland), member of the Board of Directors of the Human Vaccine Project (HVP, New York, USA), of Fondation Mérieux (Lyon, France) and of the association Solidarité Thérapeutique et Initiatives pour la Santé (Solthis, Paris, France). She is an independent non-executive Director of bioMérieux (Lyon, France). She participates in the scientific councils of several organizations active in the field of health. Until June 2017, Dr Kieny served as Assistant Director-General for Health Systems and Innovation at the World Health Organization. Her leadership at WHO included coordinating WHO's R&D efforts during the Ebola epidemic in West Africa from 2014 to 2016 and she conceptualized the WHO R&D Blueprint, a global preparedness plan for emerging disease outbreaks. Prior to joining WHO, Marie-Paule Kieny held leading research positions in the public and private sectors in France. Dr Kieny obtained her PhD in microbiology (1980) at the University of Montpellier, France. She has published more than 350 articles and reviews, mainly in the fields of infectious diseases, immunology, vaccinology and health systems. Dr. Kieny was awarded the title of Chevalier de l'Ordre National de la Légion d'honneur in France in 2016, and of Chevalier de l'Ordre National du Mérite in France in 2000. She received an honorary doctorate from the Autonomous University of Barcelona (Spain) in 2019 and was awarded the Inserm International Prize in 2017, the Generation 2000-Impact Médecin Prize in 1994 and the Rhône-Poulenc Innovation Prize in 1991.

MONTH	DATE	TIME	SESSION	SESSION TITLE
Nov 2020	05 Nov	21.00- 23.00 (BKK)	WS202	Making International Intellectual Property and Trade Regimes Work to Address the Health Response to COVID-19